The sarcomatoid variant of urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARCs and 84 cases of conventional urothelial carcinomas (UCs), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs showed a distinct mutational landscape with enrichment of TP53, RB1, and PIK3CA mutations.
SUMMARY
The sarcomatoid variant of urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARCs and 84 cases of conventional urothelial carcinomas (UCs), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs showed a distinct mutational landscape with enrichment of TP53, RB1, and PIK3CA mutations.
They were related to the basal molecular subtype of conventional UCs and could be divided into epithelial/basal and more clinically aggressive mesenchymal subsets based on TP63 and its target genes expression levels. Other analyses revealed that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of cell cycle and EMT networks, and nearly half exhibited a heavily infiltrated immune phenotype. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer.
INTRODUCTION
Bladder cancer is the ninth most common cancer worldwide, affecting 430,000 people and resulting in 165,000 deaths annually 1 . In the United States, it is the fourth most common cancer in men, with an estimated incidence of 81,000 new cases in 2018 2 . More than 90% of bladder cancers are urothelial carcinomas (UCs), which originate from precursor lesions in the epithelial layer of the bladder, called the urothelium 3 . They progress along two distinct tracks, referred to as papillary and non-papillary, that represent clinically and molecularly different forms of the disease 4 . Non-invasive papillary tumors have a high tendency for recurrence, which necessitates lifetime surveillance that is both intrusive and costly to the patient. Non-papillary carcinomas are clinically aggressive, exhibiting a high propensity for invasive growth, and a large proportion of them are lethal owing to metastatic spread 5 . We showed that papillary tumors are almost exclusively of a luminal molecular subtype that recapitulates the expression pattern of markers characteristic of normal, intermediate, and terminal urothelial differentiation 6 . In contrast, nonpapillary UCs are of a basal molecular subtype and exhibit an expression pattern of genes characteristic of the normal basal urothelial layer. Molecular subtyping has shown that invasive UCs can be almost equally divided into luminal and basal subtypes that have distinct clinical behaviors and responses to frontline chemotherapy [6] [7] [8] [9] . In addition to conventional UCs, many microscopically distinct bladder cancer variants have been described, and in general they are thought to develop via progression of conventional disease 3, 10 . The most frequent of these variants are the sarcomatoid, small cell, and micropapillary, all of which are clinically more aggressive than conventional UCs and require uniquely tailored therapeutic management, which is often unavailable 3, 5, 10 .
In this report, we focus on one of these more common variants, referred to as sarcomatoid carcinoma (SARC) 3, 10 . SARC represents, in various published series, 5-15% of bladder cancer and frequently coexists with conventional UC 11, 12 . Clinically, it has a predilection for early metastatic spread to distant organs, and it is associated with shorter survival when compared to conventional UC [10] [11] [12] . Here, we report on the genome-wide characterization of bladder SARC, including its miRNA, gene expression, and whole-exome mutational profiles, which identified unique molecular features associated with its aggressive nature that may be relevant for the early detection and treatment of this highly lethal variant of bladder cancer.
RESULTS
Twenty-eight paraffin-embedded SARC tissue samples and 84 invasive conventional bladder UC samples from the MD Anderson Cancer Center cohort were analyzed retrospectively. A cohort of 408 muscle-invasive bladder cancers in The Cancer Genome Atlas (TCGA) was used as a reference. The samples were characterized by clinical and pathological data as well as by several genomic platforms. Sufficient high-quality DNA was available for 13 SARC cases and 5 paired SARC/conventional UC cases for whole-exome sequencing. Gene expression profiling was performed on all of the cases using Illumina's DASL platform and the data were merged with those obtained from a cohort of 84 conventional UCs. Panel quantitative reverse-transcription polymerase chain reaction was used to analyze the miRNA expression levels of all 28 SARC samples and 58 conventional UC samples.
Mutational Signature
The mutational profile of conventional UC was characterized by significant levels of recurrent somatic mutations in 30 genes ( Figure 1A) . The 10 most frequently mutated genes in UC were TP53 (47%), ARID1A (25%), KDM6A (22%), PIK3CA (22%), RB1 (17%), EP300 (15%), FGFR3 (14%), STAG2 (14%), ELF3 (12%), and CREBBP (11%). The overall mutational landscapes of luminal and basal bladder UC were similar, but several mutated genes were distinctively enriched in specific molecular subtypes. Mutated FGFR3, ELF3, CDKN1A, and TSC1 genes were enriched in luminal tumors, whereas mutated TP53, RB1, and PIK3CA genes were enriched in basal tumors ( Figure 1A) . SARCs showed high overall mutational rates (median mutational frequency 259 with 174 interquartile range) and their significantly mutated genes were similar to those observed in conventional UC ( Figure 1B; Table S1 ). However, the top three genes -TP53 (72%), PIK3CA (39%), and RB1 (39%) -were mutated at significantly higher frequencies in SARCs than they were in conventional UCs (p<0.01). This suggests that SARC evolved from precursor conventional UC carrying these mutations and that mutations in these genes may drive the progression process. Several of the genes that are frequently mutated in conventional UC, including ARID1A, KDM6A, EP300, ELF3, and CREBBP, were not mutated in SARC, and these genes are involved in chromatin remodeling [13] [14] [15] [16] [17] [18] . In general, as a group, chromatin-remodeling genes were not mutated in SARC. Instead, SARC carried frequent mutations of MYO1F (33%), CNGB1 (22%), FXR1 (22%), RBM5 (22%), SEMA3D (22%), TTBK2 (22%), and ZNF90 (22%), which are involved in cellular motility, RNA binding, transmembrane ion channeling, kinase activity, and signaling [19] [20] [21] [22] [23] [24] [25] . The functional significance of the mutations of these genes for sarcomatoid progression remains unclear but they are attractive candidates for future mechanistic studies. Interestingly, FGFR3 mutations, which were present in 14% of conventional UCs, were not present in SARC. Nearly all mutations present in the SARCs were also present in the paired precursor conventional UCs of the same patients, indicating that the SARC and the presumed precursor lesions were clonally related.
Mechanisms of Mutagenesis
To further characterize the mutational process associated with progression from conventional UC to SARC, we examined six single-base substitutions (C>A, C>G, C>T, T>A, T>C, and T>G) in all cancer samples 26, 27 . The results revealed that SARCs were enriched with C>T mutations as compared with conventional UCs, and this increase was already apparent in the precursor conventional UCs that were associated with SARCs ( Figure 1C, D) . Analyses of Sanger mutational signatures 28 revealed the presence of six dominant signatures in the conventional UCs in the TCGA cohort: signatures 1, 2, 3 (BRCA1/2 mutagenesis), 13 (APOBEC), 19, and 30 ( Figures 1F and 1G) . Clustering separated the conventional tumors into two subsets (α and β ) that were characterized by different levels of signature 13 (APOBEC) prevalence. In contrast, SARCs and paired precursor conventional UCs were characterized by the uniform dominance of signature 1, which was present in all SARC and precursor conventional UC samples ( Figure   1H ). In addition, clustering segregated SARCs into two subsets, and they were also characterized by different levels of APOBEC activity. Mutagenesis signatures 1 and 19 were significantly enriched in SARCs as compared with conventional UC ( Figure 1I ). Overall, these data reinforce the idea that SARCs evolve from a distinct subset of conventional UCs.
Gene Expression Profile
Messenger RNA (mRNA) expression profiling revealed that more than 6,000 genes were differentially expressed between SARC and UC. We performed multiple unsupervised clustering analyses using all the differentially expressed genes in SARC and performed similar analyses using the top 100 and top 10 upregulated and downregulated genes. All these analyses separated SARC and UC into two distinct clusters (Figures S1A and S1B). One cluster contained conventional UC almost exclusively, whereas the other cluster contained most of the SARCs.
Among the top upregulated genes in the SARC cluster were FAM101B (or RFLNB), UHRF1, and PHC2, all of which are members of the chromatin-remodeling superfamily 29-31 ( Figure   S1B ). The top downregulated genes included the differentiation-associated transcription factor, ELF3, and genes involved in terminal urothelial differentiation, such as uroplakins and cell adherence genes, as well as LAD1, a component of anchoring filaments in the basement membrane 32 . The median survival for the SARC patients (11 months) was significantly shorter than that of the patients with conventional UC (24 months; p=0.0326) ( Figure S1C ).
Intrinsic Molecular Subtypes
Several molecular studies, including our own, have divided bladder cancer into two molecular subtypes that preferentially express basal or luminal genes 7-9,33 . To investigate whether the intrinsic molecular types of conventional bladder UC applied to SARC, we analyzed the luminal and basal gene expression signatures in SARC. We used a previously developed classifier that includes markers of luminal and basal types 33 . The set of conventional UC was separated into two major groups (Figure 2A ). The first group, comprising 53 of the 84 samples (63%), was characterized by high mRNA expression levels of luminal markers such as KRT20, GATA3, uroplakins, ERBB2, ERBB3, PPARG, FOXA1, and XBP1 and was referred to as the luminal subtype. The remaining 31 conventional UC samples (37%) were characterized by high expression levels of basal markers such as CD44, CDH3, KRT5, KRT6, and KRT14 and were referred to as the basal subtype.
Unlike the conventional UCs, all 28 SARCs had low mRNA expression levels of the luminal genes, which suggested that they developed from a basal subtype of precursor conventional UC (Figure 2A ). In addition, nearly half of the SARCs (12; 43%) were characterized by the retained expression of basal keratins, CD44, and P-cadherin (CDH3),
whereas the remaining SARCs (16; 57%) lacked expression of canonical basal and luminal markers, and we therefore referred to them as "double-negative". This subset of SARCs shares the "mesenchymal" molecular phenotype with the claudin-low and TCGA cluster IV subtypes identified previously. 7, 8, 34 Survival analysis revealed that the double-negative/mesenchymal SARCs were the most aggressive of the molecular subtypes ( Figure 2B ). Furthermore, the mean survival duration of patients with double-negative SARC (10 months) was shorter than that of patients with basal SARC (18 months); however, this difference was not significant statistically, probably because of the limited number of cases. We verified the expression patterns of signature luminal markers (GATA3) and basal markers (P63, KRT5/6, KRT14) by immunohistochemistry using tissue microarrays containing the same cases ( Figure 2C ). The epithelial/basal SARCs were focally positive for basal markers such as p63, KRT5/6, and KRT14 and were negative for the signature luminal marker GATA3. In contrast, the purely mesenchymal double-negative SARCs were immunohistochemically negative for all luminal and basal markers, consistent with the RNA expression data.
Canonical and Upstream Regulator Pathways
In order to identify candidate mechanisms underlying the progression to the SARC phenotype, 
Immune Infiltrate
Immune checkpoint blockade is clinically active in about 15% of patients with advanced bladder cancer, where response is associated with high tumor mutational burden (TMB), the "genomically unstable" luminal subtypes, and infiltration with activated cytotoxic T lymphocytes. [35] [36] [37] Given the relatively high mutational frequencies observed in SARCs, we characterized the patterns of immune-related gene expression in them (Figure 4) . In conventional UCs, 11% (9/84) showed enrichment of an immune gene expression signature and clustered in the luminal molecular subtype. In contrast, 39% (9/28) of the SARCs demonstrated overexpression of immune signature genes and preferentially clustered in the mesenchymal double-negative subtype. The enrichment of immune gene signature in SARC as compared to conventional UC was confirmed by GSEA ( Figure 5A ). We also evaluated the expression signature of immune checkpoint ligands and their receptors 38 , including CD70 and CD27; CD80 and CTLA4; TNFSF9 and TNFRSF18; ADA and ADORA2A; and PDCD1G2 and CD274
( Figure 5B ). In general, the overexpression of these genes was present in the same group of SARCs characterized by enrichment for the overexpression of immune signature genes. Of potential therapeutic significance, SARC exhibited the enhanced expression of programmed cell death ligand PD-L1 (CD274) and mRNA overexpression of PD-L1 was observed in more than 50% (15/28) of the SARCs ( Figure 5C ). This was confirmed by immunohistochemistry, which showed strong overexpression of the PD-L1 protein ( Figure 5D ), suggesting that immune checkpoint therapy may be an attractive therapeutic option for a subset of SARC patients.
MicroRNA Expression Profile
Similar to the gene expression profile, microRNA (miRNA) expression levels were widely 
Dysregulation of the EMT Network
Microscopically, SARCs comprise mixed lineages of purely mesenchymal cells and cells with at least partial retention of an epithelial phenotype, reflecting various degrees of EMT 40 . We previously showed that TP63 controls the expression of high molecular weight keratins (KRT5, KRT6, KRT14) and suppresses EMT. 6, 41 The central role of p63 in the maintenance of epithelial phenotype and EMT was confirmed in several variants of solid tumors. [42] [43] [44] We therefore Figure 6A and Figure S4B ). Because SARCs can be divided into two subgroups i.e., SARCs that retain epithelial marker expression, reflecting partial EMT, and
SARCs that are purely mesenchymal, reflecting complete EMT, we quantified the EMT levels mesenchymal SARCs were negative for the epithelial markers, confirming these subtypes' partial and complete EMT states, respectively ( Figure 6D ). Finally, the loss of E-cadherin expression was confirmed in selected SARC samples by Western blotting (Figure 6E ).
DISCUSSION
Bladder cancer is a major source of morbidity and mortality worldwide and in the United States.
In the United States, there were approximately 17,000 deaths related to bladder cancer in 2018 2 .
Progression to SARC is associated with a high propensity for early metastasis and dismal 5-year survival rates 10-12 . In the following, we highlight essential findings concerning molecular characterizations of SARC and suggest how these findings may contribute to our understanding of its aggressive behavior as well as how they open new therapeutic possibilities.
SARCs have a high overall mutation rate similar to those of conventional UC, melanoma, and non-small cell lung cancers. 49 Our findings show that in SARC these high mutation rates are associated with mutation signature 1 and that SARCs can be separated into two subgroups, i.e., one with and one without mutation signatures of an endogenous mutagenic enzyme, APOBEC cytidine deaminase. In addition, SARCs are enriched for TP53, RB1, and PIK3CA mutations as complemented by a complex multi-layered regulatory network. 54 In physiology, EMT is responsible for multi-organ development during the embryogenesis and maintenance or regeneration of these organs in adulthood. 53 In cancer, including those originating in the bladder, EMT may be a major contributor to the aggressive behavior responsible for invasive growth and metastasis 55 . Our quantitative assessment of EMT showed that basal and double-negative SARCs had intermediate and low EMT scores, respectively, which reflected their partial and complete EMT states, and the purely mesenchymal SARCs were the most aggressive variant of the disease. At the core of this circuitry are p53 and RB, which negatively regulate EMT in solid tumors and appear to be coordinately downregulated in a large percentage of SARCs. Activation of TGFB1 and RhoA can be viewed as a synergistic mechanism complementing the loss of p53 and RB. Another central mechanism that appears to be associated with the double negative SARCs involves downregulation of p63, which positively regulates basal biomarkers (i.e. CDH3, CD44, KRT5, KRT6, and KRT14) expression and negatively regulates EMT via miR-205. 6, 41 In fact, p63 and its target genes expression levels many of which represent basal biomarkers segregate SARCs into epithelial/basal and double-negative purely mesenchymal subtypes.
Downregulation of the miR-200 family and other EMT regulatory miRNA species probably reinforces the mesenchymal phenotype of these tumors. Importantly, combined TP53 and RB1 pathways inactivation and up-regulation of EMT appear to be characteristics of the clinically aggressive bladder cancer subset with neuroendocrine phenotype recently identified in the TCGA cohort. 9 Precisely how these EMT processes are initiated and what are the molecular mechanisms that distinguish sarcomatoid from neuroendocrine progression requires further investigation.
We also found that nearly half of SARCs exhibit an expression signature associated with immune cell infiltration and overexpression of immune checkpoint receptors and their ligands, including PD-L1. This finding suggests new opportunities for immune checkpoint therapy in patients with immune-infiltrated SARCs, which are typically resistant to conventional cisplatinbased chemotherapies 5,11,12 .
On the basis of our findings, we conclude that SARCs are driven by profound dysregulation of the EMT network and that a large proportion of SARCs have an immune infiltration phenotype with upregulation of PD-L1. These features present new avenues of therapeutic potential in patients with this highly lethal variant of bladder cancer. Western blot documenting loss of E-cadherin expression in SARC. 
METHODS

Clinical information and tissue samples
Whole-exome sequencing and processing pipeline
Genomic DNA from 13 cases of SARC and five cases of paired conventional UC were used for whole-exome sequencing, which was performed on the HiSeq 2000 platform (Illumina, San Diego, CA) at MD Anderson Cancer Center's Genomics Core. The TCGA data on 408 muscleinvasive conventional UCs of the bladder were used as a reference set for mutational analyses.
BWA-MEM (version 0.7.12) was used to align reads to the hg19 reference genome. Samtools insertions/deletions 64 . Similar analyses were performed for the genome-wide expression data from the TCGA cohort (n=408), and tumors were assigned to specific molecular subtypes by applying the sets of luminal, basal, and p53 markers as described previously 33 . Mutational data were downloaded from the TCGA portal (https://tcga-data.nci.nih.gov/tcga/). MutSigCV (version 1.4; https://www.broadinstitute.org/cancer/cga/mutsig) was used to identify genes that were mutated more often than expected by chance given the background mutation processes 65 .
The significant gene list was obtained using a false discovery rate (FDR) cutoff of 0.05. The statistical significance of associations between the mutations and the molecular subtypes was assessed by the Fisher exact test.
Mutagenesis signatures
We used 432 SNVs identified in at least one sample and segregated them into six types of mutations corresponding to the following base pair substitutions: C>A, C>G, C>T, T>A, T>C, and T>G. The Fisher exact test was used to determine the distribution of these mutations in the three groups of samples corresponding to conventional UC in the TCGA cohort and paired UCs and SARCs in the sarcomatoid cohort. The genomic context of SNVs, referred to as fingerprints and which included the two flanking bases on the 5' and 3' sides to each position for a total of 96 possible mutational fingerprints, was assembled. Wilcoxon rank sum tests were used to test against the hypothesis of no difference in the frequency of any fingerprint between any two groups of mucosal samples. The Benjamini and Hochberg method was applied to control the FDR. For each sample, we used its mutational fingerprints (V) and the quadratic programming GSEA was used to evaluate the enrichment probability of the top canonical pathways and upstream regulators identified by IPA 68 . Both SARC and UC samples were classified into luminal, basal, and p53-like intrinsic molecular subtypes using an algorithm described previously 6 .
Immune gene expression signatures for SARC and conventional UC were established using unsupervised hierarchical clustering. Gene dendrogram nodes corresponding to genes characteristically expressed in specific immune cell types were identified and validated through DAVID functional annotation clustering and Ingenuity Systems Analysis (www.ingenuity.com).
Immune gene signatures were used as reported previously 69-71 .
To quantitatively assess the level of EMT, we calculated the EMT score based on a 76gene expression signature reported by Byers et al 47 . For each tumor sample, the score was calculated as a weighted sum of 76 gene expression levels:
‫ݓ‬ is the correlation coefficient between the ith gene expression in the signature and that of E-cadherin, and ‫ܩ‬ is the ith gene's normalized expression in the jth tumor sample. We centered the scores by subtracting the mean across all tumor samples so that the grand mean of the score was zero.
MiRNA analysis
MiRNA analysis was performed on 28 SARC samples and 58 
Validation studies
The expression levels of selected genes were validated on parallel tissue microarrays comprising FFPE samples of 84 UCs and 28 SARCs. The microarrays were designed and prepared as described previously and profiled by genomic platforms 51 . In brief, the tissue microarrays (two Immunostaining was performed using the Bond-Max Autostainer (Leica Biosystems, Buffalo
Grove, IL). The staining intensity was scored by two pathologists (CCG and BAC) as negative and mildly, moderately, or strongly positive. In addition, the loss of expression of E-cadherin in SARC was confirmed on selected frozen tumor samples by Western blotting. In brief, whole cell extracts of tumor tissue were analyzed by immunoblotting using an anti-CDH1 antibody (4A, 1:1000 dilution; Cell Signaling Technology, Danvers, MA).
General statistical analyses
Survival analyses were performed by Kaplan-Meier analysis and log-rank testing. Welch's t-test was used for two-sample comparison, whereas the Kruskal-Wallis test was used for multiple group comparison. For genome-wide mRNA and miRNA differential expression analysis, the Benjamini and Hochberg (BH) method was applied to control the false discovery rate (FDR). An adjusted p-value with FDR < 0.05 was considered statistically significant. ZYX  TUBB6  TUBB3  TUBB2B  TCF7L2  SRC  SORBS1  SNAI2  RAPGEF1  RAC1  MYO7A  MYL9  MYL6B  MYH3  MYH14  MYH11  JUP  HGF  FGFR1  EPN2  EGFR  CLINT1  CDH1  CDC42  BMPR2  ARPC4  ACVR1  ACTR3  ACTG2 ITK  IL2RG  ICOS  GZMM  GZMK  GZMA  EOMES  CXCR6  CST7  CORO1A  CD96  CD8A  CD7  CD6  CD3G  CD3D  CD38  CD27  CD247  CD2  CCL5  C5orf20  AMICA1  ACAP1   T Cell Cluster   TBC1D10C  SLAMF6  SLA2  S1PR4  PTPRCAP  PRF1  NKG7  IL2RG  GZMK  GZMA  CXCR6  CD96  CD8A  CD6  CD48  CD3G  CD3D  CCL5  ACAP1   CD8 Cluster   MacTH1 Cluster   TXNDC16  TRAFD1  TNFRSF1B  TEP1  TAP1  STAT5A  SQSTM1  PSME2  MAN2B1  KIF20A  ISG15  IRF8  IL6  IL1B  IFIT1  DAXX  CD40  CCL22 Dendritic Cells Cluster UP Enrichment for immune profile   TNFRSF1B  TMC8  SRGN  SPN  SPI1  SNX20  SLCO2B1  SIGLEC9  RNASE6  RASAL3  PTPRC  PLEK  PARVG  NCKAP1L  NCF4  MS4A6A  MNDA  LST1  LILRB4  LILRB2  LILRB1  LCP2  LAPTM5  ITGB2  ITGAX  IRF8  IL10RA  IKZF1  HLA−DRA  HLA−DPA1  HLA−DOA  HLA−DMB  HAVCR2  FGL2  FGD2  FERMT3  FCER1G  CSF1R  CLEC4A  CD86  CD84  CD74  CD37  CD300LF  C1QC  C1QB  ARHGAP9  ARHGAP30  ARHGAP25 
Supplementary Figure Legends
Molecular subtype
Histological subtype
